Grant: Alliance Grants
McGill University
$49,999.00
COVID-19 test chip for simultaneous detection of SARS-CoV-2 and antibodies using a single non-invasive sputum sample_x000d_ _x000d_ _x000d_ _x000d_
FY 2020-21
Summary
We propose a rapid COVID-19 test integrated within a mass-producible microfluidic chip that automates all fluidic operations, from reagent delivery and incubation to signal readout, without external equipment and power. The test uses a single self-collected, non-invasive sample by coughing, to simultaneously (1) detect the viral particles in ~30 min, and (2) quantitatively measure host-generated antibodies in ~10 min, with a single simple operation like a pregnancy test. While PCR detects RNA packaged in the matured virus, our test detects directly the viral particle, resulting in a simplified test without the need for nucleic acid extraction, while potentially increasing sensitivity. Combined with host-generated antibody measurement, our test can detect active and past infections, and those that would have been missed by PCR. Our solution strikes a balance between established technologies and innovation to meet the short timelines. With our industrial partner Sensoreal Inc. specializing in mass production and commercialization of chip-based diagnostic devices, our research is designed to address manufacturing and regulatory challenges for rapid scale-up and deployment. While 3D printing allows rapid development and testing with patient samples, Sensoreal has strong interest to further develop the validated test toward mass-production to thousands chips per day. We expect this project will lead to the fastest test that is low-cost, easy-to-use and non-invasive. Validation using patient samples will be pursued upon completion of this 6-month project along with application for regulatory approval. This test, being instrumentation-free and high-throughput, could accelerate widespread testing, rapidly identify infected individuals, including asymptomatic ones, and thus determine the true scope of the pandemic.
Program
Alliance Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
551058-2020
Name nom
Juncker, David
Department département
Biomedical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
49999
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
COVID-19 test chip for simultaneous detection of SARS-CoV-2 and antibodies using a single non-invasive sputum sample_x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
We propose a rapid COVID-19 test integrated within a mass-producible microfluidic chip that automates all fluidic operations, from reagent delivery and incubation to signal readout, without external equipment and power. The test uses a single self-collected, non-invasive sample by coughing, to simultaneously (1) detect the viral particles in ~30 min, and (2) quantitatively measure host-generated antibodies in ~10 min, with a single simple operation like a pregnancy test. While PCR detects RNA packaged in the matured virus, our test detects directly the viral particle, resulting in a simplified test without the need for nucleic acid extraction, while potentially increasing sensitivity. Combined with host-generated antibody measurement, our test can detect active and past infections, and those that would have been missed by PCR. Our solution strikes a balance between established technologies and innovation to meet the short timelines. With our industrial partner Sensoreal Inc. specializing in mass production and commercialization of chip-based diagnostic devices, our research is designed to address manufacturing and regulatory challenges for rapid scale-up and deployment. While 3D printing allows rapid development and testing with patient samples, Sensoreal has strong interest to further develop the validated test toward mass-production to thousands chips per day. We expect this project will lead to the fastest test that is low-cost, easy-to-use and non-invasive. Validation using patient samples will be pursued upon completion of this 6-month project along with application for regulatory approval. This test, being instrumentation-free and high-throughput, could accelerate widespread testing, rapidly identify infected individuals, including asymptomatic ones, and thus determine the true scope of the pandemic.